| CIRM Delays Action on Clinical Trials, Biotech Loan Changes
February 1, 2010 at 7:21 PM
|
| | The California stem cell agency today said its directors would put off until their March meeting a discussion of a proposed foray into financing of clinical trials.CIRM also said that directors would not vote this week on changes in its $500 million biotech loan program. Instead they are expected to act later on the proposal during a special telephonic meeting.Both topics are on the agenda for | | |
| LA Times on CIRM Plans to Remain 'Relevant'
February 1, 2010 at 5:00 PM
|
| | The changing focus of the California stem cell agency – with its aggressive push towards fast, tangible and marketable results and presumably away from its original emphasis on human embryonic stem cell research – was the focus of a Los Angeles Times article early last month.The Jan. 10, 2010, piece by Karen Kaplan said,"Now the institute has a more immediate goal: boosting therapies that are | | |
| Recent Comments
February 1, 2010 at 3:07 PM
|
| | For unknown reasons, our "recent comment" function to the left on this page has ceased to work properly. Consequently, some recent comments have not appeared. We are attempting to fix the problem.Meanwhile, here are some comments that have been posted in the last few days. Anonymous has left a new comment on the post "CIRM Proposes $40 Million Stem Cell "Tools" Round;...":"The 'disease in a dish' | | |
| LA Times Columnist Targets CIRM; Structural Changles Needed
February 1, 2010 at 11:18 AM
|
| | The California stem cell agency, which has "self-righteously" opposed better public oversight of its activities, should be altered to create a research program that "exemplifies not only good science, but good government," a Pulitzer Prize-winning columnist said today in the Los Angeles Times.While noting that the agency has funded "important work," Michael Hiltzik said,"...(I)t's ridiculous for | | |
| CIRM Clinical Trial and Biotech Industry Loan Plans Remain Veiled
February 1, 2010 at 10:59 AM
|
| | With only two days remaining before this week's meeting of the board of directors of the California stem cell agency, still missing publicly are any details on proposals that appear to involve hundreds of millions of dollars in taxpayer funds.The plans concernCIRM's fledgling $500 million biotech loan program and participaton in funding of clinical trials, which can cost hundreds of millions of | | |
| Correction
February 1, 2010 at 10:48 AM
|
| | The "board meeting" item on Jan. 30, 2010, incorrectly said the CIRM directors will meet on Tuesday and Wednesday of this week. They meet on Wednesday and Thursday. | | | |
No comments:
Post a Comment